Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report)'s share price traded up 1.4% during trading on Friday . The company traded as high as $24.12 and last traded at $23.94. 5,025,769 shares traded hands during trading, an increase of 25% from the average session volume of 4,032,081 shares. The stock had previously closed at $23.60.
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. Raymond James lifted their target price on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a report on Thursday, February 6th. Piper Sandler reduced their price target on Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating for the company in a report on Thursday, February 6th. Scotiabank initiated coverage on Viking Therapeutics in a report on Thursday, February 13th. They set a "sector outperform" rating and a $102.00 price objective on the stock. The Goldman Sachs Group started coverage on Viking Therapeutics in a report on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 target price for the company. Finally, Citigroup began coverage on shares of Viking Therapeutics in a research note on Friday, February 7th. They set a "neutral" rating and a $38.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Viking Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $89.75.
Check Out Our Latest Stock Report on VKTX
Viking Therapeutics Stock Up 7.4 %
The stock has a fifty day moving average price of $26.83 and a two-hundred day moving average price of $41.41. The company has a market capitalization of $2.86 billion, a price-to-earnings ratio of -25.48 and a beta of 0.84.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter in the previous year, the business earned ($0.25) EPS. As a group, research analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Viking Therapeutics news, Director Sarah Kathryn Rouan bought 1,240 shares of Viking Therapeutics stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the transaction, the director now owns 1,240 shares of the company's stock, valued at $29,946. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.70% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Blue Trust Inc. grew its holdings in Viking Therapeutics by 75.9% in the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 309 shares during the period. YANKCOM Partnership acquired a new position in shares of Viking Therapeutics in the 4th quarter valued at $33,000. Parallel Advisors LLC grew its stake in shares of Viking Therapeutics by 64.8% during the 1st quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock valued at $33,000 after buying an additional 536 shares during the period. FIL Ltd increased its holdings in shares of Viking Therapeutics by 116.8% during the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock worth $48,000 after buying an additional 648 shares during the last quarter. Finally, NBC Securities Inc. raised its position in shares of Viking Therapeutics by 222,100.0% in the 1st quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company's stock worth $53,000 after buying an additional 2,221 shares during the period. Institutional investors and hedge funds own 76.03% of the company's stock.
About Viking Therapeutics
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Articles
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
